SynapCell

Hubxchange 2023

US West Coast CNS Therapeutics Xchange

24 May - SYNAPCELL SPONSORS CNS XCHANGE 2023

HubXchange’s West Coast CNS Therapeutics Xchange 2023, brings together executives from pharma and biotech to address and find solutions to the key issues faced in developing CNS therapies.
Discussion topics will cover Novel Targets, Preclinical, Clinical Studies, Advanced Therapies and Drug Delivery. Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers!

Roundtable at a glance

How can EEG and novel cutting-edge techniques transform the way drug candidates are developed until clinical phase

  • Pitfalls in drug development: Are they evolving?
  • Making the fields of EEG and drug development more objective
  • What are the most promising areas for this marriage of AI and EEG?
  • Do precision medicines require precision measurements?

We look forward to discussing with you there !  

Meet our Panelists

Hugo MONCHAL, MSc

Scientific Sales Engineer, USA/LATAM
SynapCell

LinkedIn Profile

Hugo holds a MSc in Neuroscience and a Master’s degree in international business in science. He joined SynapCell’s business development team in 2020 and quickly became the manager of the USA and LATAM zone. His background allows him to possess skills in both neuroscience and sales. Thus, he can understand the current needs of the biopharma industry towards drug discovery for CNS disorders, and how to address them. Thanks to his experience at SynapCell, Hugo shares his insights for the development of new offers and the establishment of new business strategies.

Julien VOLLE, PhD

Head of Technology
SynapCell

LinkedIn Profile

Julien holds a PhD in Neuroscience from the University of Lyon, France. He then undertook a post-doc at the Center for Addiction and Mental Health at Toronto, Canada, followed by another post-doc at the University of Toronto. Julien has been with SynapCell since 2017 when he first started as Research and Innovation Scientist to finally be appointed in 2021 as Head of technology and Principal Scientist. He uses his extensive knowledge of neuroscience and physiology to manage R&D Preclinical projects and to develop new innovative solutions for our sponsors. With over 12 years’ experience in the field, he is well-versed in the emerging technologies and industry trends.

Can’t make it this time? So let’s have a call!